Matteo Salvatore Carlino
The University of Sydney · 687 works · 59,026 citations · h-index 83
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
- Immune checkpoint inhibitors in melanoma
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF -Mutant Metastatic Melanoma
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo